- Home
- TMO
as 11-26-2025 3:36pm EST
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
| Founded: | 1956 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 216.4B | IPO Year: | N/A |
| Target Price: | $611.19 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 17.32 | EPS Growth: | 8.54 |
| 52 Week Low/High: | $385.46 - $610.97 | Next Earning Date: | 10-22-2025 |
| Revenue: | $43,736,000,000 | Revenue Growth: | 3.22% |
| Revenue Growth (this year): | 4.28% | Revenue Growth (next year): | 5.00% |
Stock Insider Trading Activity of Thermo Fisher Scientific Inc (TMO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lagarde Michel | TMO | Executive Vice President & COO | Nov 13 '25 | Sell | $594.42 | 4,638 | $2,756,919.96 | 23,479.909 | |
| Britt Lisa P. | TMO | Sr. VP and Chief HR Officer | Nov 12 '25 | Sell | $588.27 | 1,057 | $622,135.53 | 13,087.227 | |
| Pettiti Gianluca | TMO | Executive Vice President | Nov 10 '25 | Sell | $580.00 | 2,975 | $1,725,500.00 | 21,152.223 | |
| Britt Lisa P. | TMO | Sr. VP and Chief HR Officer | Nov 7 '25 | Sell | $571.53 | 10,225 | $5,844,850.07 | 13,087.227 | |
| CASPER MARC N | TMO | Chairman & CEO | Oct 27 '25 | Sell | $566.71 | 7,250 | $4,104,241.78 | 113,762.285 | |
| CASPER MARC N | TMO | Chairman & CEO | Oct 24 '25 | Sell | $573.23 | 17,104 | $9,809,862.02 | 113,762.285 | |
| Pettiti Gianluca | TMO | Executive Vice President | Oct 24 '25 | Sell | $574.15 | 400 | $229,660.00 | 21,152.223 | |
| CASPER MARC N | TMO | Chairman & CEO | Sep 5 '25 | Sell | $500.67 | 400 | $200,201.00 | 113,762.285 | |
| Holmes Joseph R. | TMO | VP & Chief Accounting Officer | Aug 29 '25 | Sell | $492.62 | 385 | $189,661.91 | 2,603.982 |
Latest Thermo Fisher Scientific Inc News
TMO Breaking Stock News: Dive into TMO Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Thermo Fisher Scientific Prices Offering of Euro-Denominated Notes at 100% of Par Value
Simply Wall St.
3 days ago
Are Thermo Fisher Shares a Fair Deal After Key Pharma Partnerships and 14% Price Surge?
Business Wire
3 days ago
Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes
PR Newswire
3 days ago
Net Lease Office Properties Declares Special Cash Distribution of $4.10 Per Share
GlobeNewswire
3 days ago
Liquid Biopsy Market Competitive Landscape Report 2025: Recent Developments, Strategies, Sustainability Benchmarking, Product Analysis, Key Persons and Revenue
Zacks
3 days ago
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
StockStory
3 days ago
1 Cash-Producing Stock to Own for Decades and 2 Facing Headwinds
Zacks
6 days ago
Why Is Thermo Fisher (TMO) Up 0.2% Since Last Earnings Report?
Compare TMO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TMO Thermo Fisher Scientific Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.